BillionToOne, Inc. (BLLN) — Stock Price, Chart & Analysis
BillionToOne, Inc. (BLLN) is a Healthcare stock currently trading at $116.07, up 15.24% on the day. It carries a market capitalization of $5.48B and a trailing P/E ratio of 145.09. Over the past 52 weeks, BLLN has traded between $61.96 and $150.44. BillionToOne, Inc. does not currently pay a regular dividend. View the live BLLN chart, technical opinion, analyst ratings, fundamentals and latest news below.
BillionToOne, Inc. (BLLN) key data
| Price | $116.07 |
| Change (today) | +15.24% |
| Previous close | $100.72 |
| Market cap | $5.48B |
| P/E ratio (TTM) | 145.09 |
| EPS (TTM) | $0.80 |
| 52-week high | $150.44 |
| 52-week low | $61.96 |
| Avg. volume | 709.5K |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
Frequently asked questions about BillionToOne, Inc. (BLLN)
How much does one share of BillionToOne, Inc. cost?
As of the latest update, one share of BillionToOne, Inc. (BLLN) trades at $116.07 (+15.24% today).
What is BillionToOne, Inc.'s market cap?
BillionToOne, Inc. has a market capitalization of approximately $5.48B.
What is BillionToOne, Inc.'s P/E ratio?
BillionToOne, Inc. has a trailing price-to-earnings (P/E) ratio of 145.09.
What is BillionToOne, Inc.'s earnings per share (EPS)?
BillionToOne, Inc.'s trailing twelve-month EPS is $0.80.
Does BillionToOne, Inc. pay a dividend?
BillionToOne, Inc. does not currently pay a regular dividend.
What is BillionToOne, Inc.'s 52-week trading range?
Over the past year, BLLN has traded between $61.96 and $150.44.
What is the analyst price target for BillionToOne, Inc.?
The mean analyst price target for BillionToOne, Inc. is $119.75. This is informational only and not investment advice.
Latest BillionToOne, Inc. (BLLN) news
- BillionToOne Stock Jumped 12% Yesterday. Here’s What the Streets Target.News · Sep 23, 2026
- BillionToOne SVP Sells 1,416 SharesNews · Sep 21, 2026
- BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 MillionNews · Sep 17, 2026
- BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare ConferenceNews · Sep 2, 2026
- BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of OriginNews · Sep 1, 2026
- Jim Cramer Calls BillionToOne (BLLN) a “Pretty Darn Good Company”News · Aug 28, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live BLLN dashboard…